MAO-A/5-HT2AR-IN-1

MedChemExpress

®

| Cat. No.: | HY-151596 | | |
|--------------------|---|----------------|----------|
| CAS No.: | 2769156-00 | -3 | |
| Molecular Formula: | C ₃₀ H ₂₈ FN ₃ C | D ₂ | |
| Molecular Weight: | 481.56 | | |
| Target: | Monoamine Oxidase; 5-HT Receptor | | |
| Pathway: | Neuronal Signaling; GPCR/G Protein | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |

Product Data Sheet

| BIOLOGICAL ACTIV | | | | | |
|-------------------------|--|---|---|--|--|
| Description | MAO-A/5-HT2AR-IN-1 (compo | und I14) is a potent MAO-A and 5 -IN-1 is a potential antidepressa | -HT2AR dual inhibitor, with IC $_{50}$ values of 0.004 and 0.014 $\mu\text{M},$ nt agent $^{[1]}.$ | | |
| IC₅₀ & Target | MAO-A 0.004 ± 0. μM (IC ₅₀) | 5-HT _{2A} Receptor 0.014 μΜ (IC ₅₀) | MAO-B 1.05 ± 0.0 μM (IC ₅₀) | | |
| In Vitro | MAO-A/5-HT2AR-IN-1 (compound I14) (0-4 μ M, 24 h) exhibits a significant neurocytoprotective effect on the CORT-induced cell depression model ^[1] . MAO-A/5-HT2AR-IN-1 is able to occupy the active cavity of 5-HT2AR and MAO-A with multiple hydrogen bonding forces and π - π stacking interaction ^[1] . MAO-A/5-HT2AR-IN-1 exhibits low proliferation inhibitory activities against L02 cells (IC ₅₀ > 100 μ M), SH-SY5Y (IC ₅₀ > 10 μ M) and PC12 (IC ₅₀ > 10 μ M), indicating it has a good safety profile ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. [1][1] | | | | |
| | Cell Line: | PC12 cells | | | |
| | Concentration: | 4.0, 2.0, 1.0, and 0.5 μM (and 500 μM CORT) | | | |
| | Incubation Time: | 24 h | | | |
| | Result: | | e effect on PC12 cells injury at different concentrations ιp, where the best protective effect was observed at 0.5 μM. | | |
| In Vivo | MAO-A/5-HT2AR-IN-1 (0-1 μM MAO-A/5-HT2AR-IN-1 is able t in mice brain tissue ^[1] . MAO-A/5-HT2AR-IN-1 (2 mg/k | , for 7 days) improves zebrafish k o repair the damage of mice hipp g (i.v.) 10 mg/kg (i.g.); once) has a | ficantly ameliorates the depression-like behavior of mice ^[1] . bocomotion and the depression-like behavior ^[1] . bocampal neuronal cells and reduce the expression of 5-HT2AR a good clearance rate of 345.69 mL/min/kg in rats ^[1] . hethods. They are for reference only. | | |

| Animal Model: | ICR male mice (8–10 weeks old, weight 18-20 g) ^[1] | | | | |
|-----------------|--|------------------|--------------------|--|--|
| Dosage: | 10 mg/kg, 20 mg/kg | | | | |
| Administration: | For 2 weeks | | | | |
| Result: | Significantly improved depression-like behavior in mice, with the low dose group (10 mg/kg) being more potent than with the positive drug (Flu, 20 mg/kg). Had no relevant toxic effects on the liver, kidney, lung, and spleen of mice during the treatment period. | | | | |
| Animal Model: | Zebrafish (AB strain, Reserpine-induced zebrafish depression model) $^{[1]}$ | | | | |
| Dosage: | 0.1, 0.5, 1 μM | | | | |
| Administration: | Given 24 h after reserpine, for 7 days. | | | | |
| Result: | Showed that zebrafish in the I14 administered group moved significantly more distance, faster, and spent significantly more time in the upper part compared to the model group | | | | |
| Animal Model: | Sprague-Dawley rats (male) ^[1] | | | | |
| Dosage: | 2 mg/kg (i.v.) 10 mg/kg (i.g.) | | | | |
| Administration: | IV, IG; once (Pharmacokinetic Analysis) | | | | |
| Result: | Pharmacokinetic Parameters of MAO-A/5-HT2AR-IN-1 in male Sprague-Dawley rats $^{[1]}$. | | | | |
| | parameter | 2 mg/kg (i.v.) | 10 mg/kg (i.g.) | | |
| | T _{max} (h) | 0.08 ± 0.00 | 1.33 ± 0.33 | | |
| | C _{max} (ng/mL) | 673.33 ± 25.41 | 99.67 ± 6.01 | | |
| | AUC ₀₋₂₄ (ng/mL·h) | 2230.67 ± 153.78 | 490.67 ± 70.43 | | |
| | AUC _{0-inf} (ng/mL·h) | 2322.67 ± 178.02 | 504.00 ± 71.08 | | |
| | t _{1/2} (h) | 6.31 ± 0.55 | 5.22 ± 0.79 | | |
| | CL (mL/min/kg) | 14.54 ± 1.20 | 345.69 ± 53.40 | | |
| | MRT _{inf} (h) | 4.19 ± 0.14 | 4.94 ± 0.36 | | |
| | F (%) | | 4.40 | | |

REFERENCES

[1]. Sun X, Li N, et al. Development of MAO-A and 5-HT2AR Dual Inhibitors with Improved Antidepressant Activity. J Med Chem. 2022 Oct 13;65(19):13385-13400.

Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA